Massive Transfusion Protocols

For decades, initial trauma resuscitation prioritized crystalloid infusion and packed red blood cells, with plasma and platelets given only after laboratory evidence of coagulopathy. Military surgeons in Iraq and Afghanistan observed that this approach led to dilutional coagulopathy and worsened hemorrhagic death. Retrospective analyses from combat support hospitals demonstrated that soldiers who received higher ratios of plasma and platelets to red blood cells had dramatically improved survival. These battlefield observations from Borgman and colleagues in 2007, showing a mortality reduction from 65% to 19% with high-ratio transfusion, catalyzed a fundamental rethinking of civilian trauma resuscitation.

The PROPPR trial (Pragmatic, Randomized Optimal Platelet and Plasma Ratios) provided the definitive prospective evidence for balanced resuscitation. This landmark multicenter RCT randomized 680 patients predicted to require massive transfusion to either 1:1:1 (plasma:platelets:RBCs) or 1:1:2 ratios. While overall 24-hour and 30-day mortality did not differ significantly, the 1:1:1 group achieved hemostasis more rapidly and had significantly fewer deaths from exsanguination at 24 hours. The trial established 1:1:1 as the standard ratio for massive transfusion protocols worldwide and validated the military experience in a rigorous civilian trial. Importantly, there was no increase in transfusion-related complications with the higher plasma and platelet ratios.

Two major extensions have refined massive transfusion practice. First, whole blood has re-emerged as a resuscitation product, with military and civilian studies showing that low-titer group O whole blood provides balanced hemostatic resuscitation in a single product, simplifying logistics and potentially improving outcomes. The STORHM trial demonstrated feasibility and safety of prehospital whole blood transfusion. Second, viscoelastic hemostatic assays (TEG and ROTEM) have enabled goal-directed transfusion, allowing clinicians to identify specific coagulation deficits and target therapy rather than empirically transfusing fixed ratios. The ITACTIC trial compared viscoelastic-guided versus conventional coagulation test-guided transfusion in trauma, though it did not demonstrate a significant mortality benefit for the viscoelastic approach.

Major trauma guidelines worldwide now mandate institutional massive transfusion protocols (MTPs) with balanced blood product ratios. The European Guideline on Management of Major Bleeding and Coagulopathy following Trauma (5th edition) recommends a target ratio of plasma:RBC of at least 1:2, with viscoelastic testing to guide further component therapy. The American College of Surgeons TQIP Best Practice Guidelines mandate that all trauma centers have a formal MTP with predefined activation criteria and product ratios. Both guidelines recommend early activation before laboratory confirmation of coagulopathy, recognizing that empiric balanced resuscitation saves lives in the critical first hour.

Current practice integrates balanced empiric transfusion with goal-directed refinement using point-of-care viscoelastic assays. Whole blood programs are expanding rapidly in both military and civilian trauma systems, with ongoing trials evaluating cold-stored low-titer O-whole blood versus component therapy. Prehospital blood product administration is increasingly standard in mature trauma systems, bringing hemostatic resuscitation to the point of injury. Fibrinogen supplementation (cryoprecipitate or fibrinogen concentrate) has emerged as a critical early adjunct, with the CRYOSTAT-2 trial informing practice. The frontier of research includes dried plasma products for austere environments, artificial oxygen carriers, and machine learning algorithms to predict massive transfusion need before clinical decompensation.